Resmetirom shows antifibrotic efficacy in MASH via AI-based quantification
22 Jul 2026
bởiStephen Padilla
Treatment with the thyroid hormone beta agonist resmetirom significantly improves qFibrosis continuous values (qFC), categorical stages (qFS), and individual collagen features associated with fibrosis progression at week 52 compared with placebo in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), as shown in the phase III MAESTRO-NASH trial.